Description of the Invention
From the 60M epileptics worldwide, about 30% of them are/will be nonresponsive to all current traditional anti-seizure medication, thus representing a large unmet medical need and a major economic burden. The epilepsy drug market is a large ($4.5B) and growing market (CAGR of 3.8%) to reach $5.5B by 2022. Despite the 25+ drugs and generics, epilepsy remains an underserved market where medication has failed to address side effects, compliance, and comorbidity issues.
By linking chemically two or more brain active constituents from both anti-seizure medication and diet therapy (clinically effective at treating drug resistant patients), Ketogen provides new chemical entities (NCEs) with unique,multiple additive/synergistic (including new) anti-seizure mechanisms of action (MOA) to patients suffering from difficult to control seizures. Our lead asset, KG-130, has shown broad, well differentiated anti-epileptic properties across multiple animal seizure models. A new therapeutic, once daily oral pill with enhanced efficacy and safety that is able to get refractory patient controlled would mark a clear breakthrough in epilepsy management. Ketogen is the only company exploiting the interactions between diet and drug therapies.
Current focus is on patients with difficult to control seizures (orphan pediatric epilepsy disorders).
Ketogen filed two composition of matter patents on two distinct chemical series based on the additive and synergistic interactions between specific AEDs and ketone generating groups. One was granted and reached the PCT stage. Ketogen owns all IP rights and has full freedom to operate.